Advertisement

Document › Details
Activiomics Ltd.. (11/22/12). "Press Release: Activiomics Signs Research Agreement with Kyowa Hakko Kirin as Part of Its Strategic Partnership with BioFocus".
Activiomics today announces it has signed a research agreement with the Japanese pharmaceutical company Kyowa Hakko Kirin. Under the agreement, Activiomics will apply its novel TIQUAS phosphoproteomics platform to elucidate signalling mechanisms of lead compounds in relevant cell-based systems. This agreement was signed as part of Activiomics' recently announced strategic partnership with BioFocus.
Activiomics partners with Pharma and Biotech using its innovative mass spectrometry based methods to analyse and interpret cell signalling pathway activity, generating high value information for the pharmaceutical and biotechnology industry.
"We've engaged with Activiomics because we recognise that Activiomics' label free phosphoproteomics approach can provide unique insights into signalling pathway activity, information that can complement and extend our existing gene expression datasets. This technology will enable us to better understand cell signalling mechanisms of our lead compounds and could enable us to identify important biomarkers" said Etsuo Ohshima, Ph.D., managing officer and vice president, head, research division at Kyowa Hakko Kirin.
Dr Neil Torbett, COO of Activiomics, said: "We are delighted to have signed this agreement with Kyowa Hakko Kirin. This is a further endorsement of our technology platform and also represents Activiomics' first entry into the Japanese market. Activiomics has received invaluable support from BioFocus in establishing this collaboration, a clear demonstration of our strategic partnership in action".
Dr Chris Newton, Managing Director of BioFocus, commented "BioFocus is pleased to have participated in the signing of this deal, which we intend to be the first of many. Future deals will add together BioFocus' drug discovery capabilities and Activiomics' phosphoproteomics platform for the furtherance of our clients' projects".
For more information, please contact:
Activiomics Ltd. Mark Warne, CEO, Tel: +44 845 5195 091
BioFocus: Chris Newton, Managing Director, Tel: + 44 1799 533 500
Record changed: 2019-06-09 |
Advertisement

More documents for Retroscreen Virology (Group)
- [1] Retroscreen Virology Group plc. (3/4/14). "Press Release: Acquisition [of Activiomics Ltd.]"....
- [2] Activiomics Ltd.. (9/30/13). "Press Release: Activiomics Extends Capability to Clinical Biomarker Discovery and Appoints CEO". London....
- [3] BioFocus. (9/19/13). "Press Release: Activiomics Extends Research Agreement with Kyowa Hakko Kirin as Part of Its Strategic Partnership with BioFocus"....
- [4] BioFocus. (7/25/12). "Press Release: BioFocus Expands Its Drug Discovery Offering with Proteomics Technology from Activiomics"....
- [5] Activiomics Ltd.. (3/27/12). "Press Release: Biomarker Specialist Activiomics Appoints Dr Trevor Nicholls as Non-executive Chairman". London....
- [6] Activiomics Ltd.. (3/14/11). "Press Release: Biomarker Specialist Activiomics Receives Investment from IP Group plc. Investment in Queen Mary, University of London Spin-out to Fund Growth Strategy"....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com
Advertisement
![Picture [iito] Männer Ballett 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-maenner-ballett.jpg)
» top